CurrentCignaPolicy IP0396

Oral tetracycline antibiotics (dermatology indications) - Coverage Criteria

Medical necessity and authorization criteria for a range of oral tetracycline and minocycline products (for acne, rosacea, and other uses) for Cigna-administered health plans; affects prescribers and prior authorization reviewers.

Policy Summary

PayerCigna

PolicyOral tetracycline antibiotics (dermatology indications) - Coverage Criteria

Policy CodePolicy IP0396

Change TypeNo material change

Effective Date

Next Review Date

Key ActionSubmit prior authorization with diagnosis, prior therapy history (specific trials/intolerances/contraindications), and for reauthorization document beneficial response.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

~20listed tetracycline/minocycline products included

2named combination kits listed

6 moinitial authorization duration

12 moreauthorization duration

benefit shownreauthorization requirement

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

exclusions statement

Coverage and Medical Necessity Criteria

Acticlate criteria (pattern repeated for many products)

Acticlate (example) — Covered when ONE of the following:

Overall

1. Acne diagnosis
- a: The individual has had an inadequate response or is intolerant to ONE of the following: doxycycline monohydrate 50 mg or 100 mg; OR doxycycline hyclate 50 mg, 75 mg, 100 mg, or 150 mg.
- b: The individual has had an inadequate response, contraindication, or is intolerant to ONE of the following: minocycline 50 mg, 75 mg, or 100 mg; OR minocycline ER 55 mg, 65 mg, 80 mg, 105 mg, or 115 mg.
- c: The individual has had an inadequate response, contraindication, or is intolerant to tetracycline 250 mg or 500 mg.
2. Non-acne diagnosis
- a: Individual is currently receiving Acticlate.
- b
  - i: The individual has had an inadequate response or is intolerant to ONE of the following: doxycycline monohydrate 50 mg or 100 mg; OR doxycycline hyclate 50 mg, 75 mg, 100 mg, or 150 mg.
  - ii: The individual has had an inadequate response, contraindication, or is intolerant to ONE of the following: minocycline 50 mg, 75 mg, or 100 mg; OR minocycline ER 55 mg, 65 mg, 80 mg, 105 mg, or 115 mg.
  - iii: The individual has had an inadequate response, contraindication, or is intolerant to tetracycline 250 mg or 500 mg.

General acne coverage logic

Product-specific coverage generally requires meeting similar step/failure/intolerance logic

Common acne criteria

1: Inadequate response or intolerance to doxycycline options OR inability to take the bioequivalent doxycycline product due to a formulation (inactive ingredient) difference that would cause a significant allergy or serious adverse reaction (where specified).
2: Inadequate response, contraindication, or intolerance to ONE of the following: minocycline 50 mg, 75 mg, or 100 mg; OR minocycline ER 55 mg, 65 mg, 80 mg, 105 mg, or 115 mg (some products require trial of the bioequivalent generic minocycline and document formulation intolerance).
3: Inadequate response, contraindication, or intolerance to tetracycline 250 mg or 500 mg.

Oracea criteria

Oracea (rosacea)

Oracea

1: Documented diagnosis of rosacea.
2
- a: Individual is currently receiving doxycycline monohydrate 40 mg biphasic release capsules (Oracea).
- b: BOTH of the following (i and ii): the individual has had an inadequate response or is intolerant to doxycycline monohydrate 50 mg tablets; AND the individual has had an inadequate response, contraindication, or is intolerant to minocycline 55 mg extended-release.

Reauthorization criteria

Reauthorization

Reauthorization: Initial criteria met AND documentation of beneficial response.

Requests for tetracycline antibiotics for indications other than those specified in this policy are not supported. Tetracycline antibiotics are considered experimental, investigational or unproven for ANY other use.

Per guideline recommendations, systemic antibiotics should not be used as monotherapy for acne. Systemic tetracycline-class antibiotics should be prescribed in conjunction with a topical product and for the shortest possible duration to minimize bacterial resistance.

Included Products and Codes

Included productsmixed

Acticlate	doxycycline hyclate 75 mg and 150 mg tablets
Doryx	doxycycline hyclate 50 mg, 80 mg, 120 mg, 150 mg, and 200 mg delayed release tablets
Doryx MPC	doxycycline hyclate 60 mg and 120 mg delayed release tablets
Doxycycline DR	doxycycline hyclate 50 mg, 75 mg, 80 mg, 100 mg, 150 mg and 200 mg delayed release tablets
Minolira ER	minocycline 105 mg and 135 mg extended-release tablets
Monodox	doxycycline monohydrate 50 mg, 75 mg, and 100 mg capsules
Oracea	doxycycline monohydrate 40 mg biphasic release capsules
Solodyn	minocycline 55 mg, 65 mg, 80 mg, 105 mg, and 115 mg extended release tablets
TargaDOX	doxycycline hyclate 50 mg tablets
tetracycline 250 mg	tetracycline 250 mg tablets

1–10 of 14

1/2

Prior Authorization Requirements and Provider Guidance

Prior Authorization

Prior Authorization Required

Prior authorization is required when the policy criteria apply for tetracycline-class antibiotics and branded products listed under this policy. Submit a PA request when coverage criteria (diagnosis, prior therapy trials, or current receipt of product) are met to avoid claim denials.

Applies to doxycycline and minocycline products and branded formulations listed in policy IP0396
PA required for initial and reauthorization requests when criteria/clinical benefit documented

Prior Authorization

Prior Authorization for Antibiotic Kits

Prior authorization is required for antibiotic-containing kits that include doxycycline or minocycline components.

Examples: Avidoxy™ DK defence™ Kit (doxycycline monohyclate 100 mg component); Morgidox® Kit (doxycycline hyclate 50 or 100 mg component)
PA applies to kits when the antibiotic component is subject to the policy

Background and Context

Tetracyclines (including doxycycline, minocycline, sarecycline and older tetracycline formulations) are broad‑spectrum oral antibiotics with both antibacterial and anti‑inflammatory effects and are commonly used in dermatology for acne and related inflammatory conditions. Clinical guidance notes that doxycycline, minocycline, and sarecycline have similar efficacy and are often preferred over older tetracycline formulations. Use should follow guideline principles—limited duration, combined with topical therapy when used for acne—and requests outside the policy‑specified indications may be considered experimental or investigational.

Product Definitions and Key Terms

Oracea — doxycycline monohydrate 40 mg biphasic release description

Generic nameDoxycycline monohydrate 40 mg, biphasic (immediate-release/delayed-release) capsules

BrandOracea

Indication (exact)Indicated for treatment of inflammatory lesions (papules and pustules) of rosacea in adults

PopulationAdults with rosacea

Not indicated for acneOracea and the 40 mg doxycycline formulation are indicated only for inflammatory lesions of rosacea (not for general acne indications)

Minolira/Solodyn/Ximino — minocycline product indications and age ranges

Policy Summary

PayerCigna

PolicyOral tetracycline antibiotics (dermatology indications) - Coverage Criteria

Policy CodePolicy IP0396

Change TypeNo material change

Effective Date

Next Review Date

Key ActionSubmit prior authorization with diagnosis, prior therapy history (specific trials/intolerances/contraindications), and for reauthorization document beneficial response.

SourceLink

On This Page

Note

Antibiotic Monotherapy and Duration

Systemic antibiotics should not be used as monotherapy and should be used for the shortest possible duration consistent with clinical guidelines to minimize bacterial resistance.

Avoid antibiotic monotherapy — combine systemic antibiotics with topical therapy for acne management
Use systemic antibiotics for the shortest duration necessary; document planned treatment duration

Documentation Required

Required Clinical Documentation

Include complete clinical documentation with all PA requests: diagnosis, prior therapy history, rationale for selection, and evidence of benefit for reauthorization.

Documented diagnosis relevant to policy criteria (e.g., acne, rosacea, other covered indication)
Details of prior therapies tried, doses, durations, and reason for failure/intolerance (e.g., inadequate response, contraindication, allergy)
For reauthorization: documentation of clinical benefit and continued need

Documentation Required

Kit Component Documentation

When submitting PA for a kit, document the kit components and the intended use of each item in the kit.

List the antibiotic component (name, strength, quantity) and the non-antibiotic components (e.g., cleanser, sunscreen)
State the intended clinical use (e.g., management of acne) and whether systemic antibiotic within the kit is being used with topical therapy

Step Therapy

Step Therapy Note

Step therapy requirements may apply on legacy or specific formularies; verify member’s benefit plan for possible step edits before submission.

Some branded products require prior trials of generic or alternate tetracyclines per formulary step edits
If step therapy is applicable, include documentation of trials and reasons for failure/intolerance to prior steps

Prior Authorization

Topical Plus Systemic Therapy

Consistent with guideline recommendations, systemic antibiotics should be used together with topical therapy for acne; indicate concurrent topical regimen in the PA when applicable.

Document concurrent topical therapy (agent and duration) when systemic antibiotic is requested for acne
Requests that propose systemic antibiotic alone for acne are subject to review and may be denied without evidence of combined topical therapy

ProductsMinolira, Solodyn, Ximino (minocycline formulations)

Indication (exact)Indicated for treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris

Age rangesMinolira, Solodyn, Ximino: indicated for use in patients ≥ 12 years of age

Comparative efficacyDoxycycline, minocycline, and sarecycline are similar in efficacy and more effective than tetracyclines (per AAD guidance)

Avidoxy DK defence Kit — kit contents and intended acne management use

Kit nameAvidoxy DK defence Kit

Antibiotic componentDoxycycline monohydrate 100 mg

Included topical itemsdefence acne wash (deep-cleansing foaming emollient acne wash); defence solare SPF 30+ (sun block)

Intended useFor management of acne

Morgidox Kit — kit contents (doxycycline + cleanser) intended for acne management

Kit nameMorgidox Kit

Antibiotic componentDoxycycline hyclate 50 mg or 100 mg

Included topical itemAccuWash moisturizing cleanser

Intended useFor management of acne